Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting

References

• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30:279–293.
   PubMed Web of Science ®Google Scholar
• Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892–909.
   PubMed Web of Science ®Google Scholar
• Chien WT, Yip AL. Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments. Neuropsychiatr Dis Treat. 2013;9:1311–1332.
   PubMed Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171–1180.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19:3–5.
   PubMed Web of Science ®Google Scholar
• Kim B, Lee SH, Yang YK, et al. Long-acting injectable antipsychotics for first-episode of schizophrenia: the pros and cons. Schizophr. Res Treatment. 2012;2012:560836.
   Google Scholar
• European Medicines Agency. Paliperidone palmitate (Xeplion): European public assessment report. EMA/472922/2012; 2012 [cited 2016 Aug 9]. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002105/WC500103318.pdf
   Google Scholar
• AGENZIA ITALIANA DEL FARMACO. Regime di rimborsabilità e prezzo di vendita del medicinale XEPLION (paliperidone)-autorizzata con procedura centralizzata europea dalla Commissione Europea. (Determinazione/C 177/2012). Gazzetta n. 52 del 2 marzo 2012; 2012 [cited 2016 Aug 9]. Available from: http://www.gazzettaufficiale.biz/atti/2012/20120052/12A02249.htm
   Google Scholar
• Citrome L. Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract. 2010;64:216–239.
   PubMed Web of Science ®Google Scholar
• Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs. 2010;24:227–244.
   PubMed Web of Science ®Google Scholar
• Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2010;6:561–572.
   PubMed Web of Science ®Google Scholar
• Chue P, Chue J. A review of paliperidone palmitate. Expert Rev Neurother. 2012;12:1383–1397.
   PubMed Web of Science ®Google Scholar
• Chue PS, MacKenzie EM, Chue JA, et al. The pharmacology and formulation of paliperidone extended release. Expert Rev Neurother. 2012;12:1399–1410.
   PubMed Web of Science ®Google Scholar
• Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evid. 2007;2:261–271.
   Google Scholar
• Alphs L, Bossie CA, Sliwa JK, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry. 2011;10:12.
   PubMed Web of Science ®Google Scholar
• Álamo C, López-Muñoz F. The pharmacological role and clinical applications of antipsychotics’ active metabolites: paliperidone versus risperidone. Clin Exp Pharmacol. 2013;3:117.
   Google Scholar
• Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30:235–244.
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116:107–117.
   PubMed Web of Science ®Google Scholar
• Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1002–1008.
   PubMed Web of Science ®Google Scholar
• Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry. 2011;35:218–226.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012;15:107–118.
   PubMed Web of Science ®Google Scholar
• Cordiner M, Shajahan P, McAvoy S, et al. Effectiveness of long-acting antpsychotics in clinical practice: 1. A retrospective 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol. Ther Adv Psychopharmacol. 2016;6:22–32.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of paliperidone palmitate vs. haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014;311:1978–1987.
   PubMed Web of Science ®Google Scholar
• Hargarter L, Cherubin P, Bergmans P, et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Progr Neuropsychopharmacol Biol Psychiatry. 2015;58:1–7.
   PubMed Web of Science ®Google Scholar
• Schreiner A, Bergmans P, Cherubin P, et al. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents. Clin Ther. 2014;36:1372–1388.
   PubMed Web of Science ®Google Scholar
• Schreiner A, Bergmans P, Cherubin P, et al. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics. J Psychopharmacol. 2015;29:910–922.
   PubMed Web of Science ®Google Scholar
• Taylor D, Olofinjana O. Long-acting paliperidone palmitate-interim results of an observational study of its effect on hospitalization. Int Clin Psychopharmacol. 2014;29:229–234.
   PubMed Web of Science ®Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76:554–561.
   PubMed Web of Science ®Google Scholar
• Fu DJ, Turkoz I, Simonson RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry. 2015;76:253–262.
   PubMed Web of Science ®Google Scholar
• Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168:498–504.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Loze JY, Forray C, et al. Multidimensional assessment of functional outcomes in schizophrenia: results from QUALIFY, a head-to-head trial of aripiprazole once-monthly and paliperidone palmitate. Int J Neuropsychopharmacol. 2017;20:40–49.
   PubMed Web of Science ®Google Scholar
• Attard A, Olofinjana O, Cornelius V, et al. Paliperidone palmitate long-acting injection-prospective year-long follow-up of use in clinical practice. Acta Psychiatr Scand. 2014;130:46–51.
   PubMed Web of Science ®Google Scholar
• Bressington D, Stock J, Hulbert S, et al. A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates. Int Clin Psychopharmacol. 2015;30:230–236.
   PubMed Web of Science ®Google Scholar
• Chue P, Chue J. A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder. Ther Clin Risk Manag. 2016;12:109–116.
   PubMed Web of Science ®Google Scholar
• Whale R, Pereira M, Cuthbert S, et al. Effectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12-month naturalistic cohort study. J Clin Psychopharmacol. 2015;35:591–595.
   PubMed Web of Science ®Google Scholar
• Nikolić N, Page N, Akram A, et al. The impact of paliperidone palmitate long-acting injection on hospital admissions in a mental health setting. Int Clin Psychopharmacol. 2017;32:95–102.
   PubMed Web of Science ®Google Scholar
• Vincent PD, Demers MF, Doyon-Kemp V, et al. One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada. Schizophr Res. 2017;185:96–100.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez A, Catalán R, Penadés R, et al. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability -a review. Patient Prefer Adherence. 2015;9:695–706.
   PubMedGoogle Scholar
• Si T, Zhang K, Tang J, et al. Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study. Neuropsychiatr Dis Treat. 2015;22:1483–1492.
   Google Scholar
• Di Lorenzo R, Cameli M, Bolondi M, et al. Paliperidone palmitate treatment in outpatient care setting: a naturalistic study. Psychopharmacol Bull. 2016;46:36–53.
   PubMedGoogle Scholar
• Ministero del lavoro, della salute e delle politiche sociali. Classificazione delle malattie, dei traumatismi, degli interventi chirurgici e delle procedure diagnostiche e terapeutiche: versione italiana della ICD-9-CM (International classification of diseases, 9th revision, Clinical modification, 2007). Roma, Italy: Istituto poligrafico e Zecca dello Stato; 2008.
   Google Scholar
• Guy W. ECDEU Assessment manual for psychopharmacology. Rockville (MD): Department of health, education, and welfare public health service alcohol, drug abuse, and mental health administration; 1976.
   Google Scholar
• Luborsky L. Clinician's judgments of mental health. Arch Gen Psychiatry. 1962;7:407–417.
   PubMed Web of Science ®Google Scholar
• Stata Version 12. Stata statistical software: release 12. College Station (TX): Stata Corp LP; 2011.
   Google Scholar
• Wang D, Fu DJ, Wu X, et al. Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia. Pharmacogenet Genom. 2015;25:173–185.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo R, Sagona M, Landi G, et al. The revolving door phenomenon in an Italian acute psychiatric ward: a 5-year retrospective analysis of the potential risk factors. J Nerv Ment Dis. 2016;204:686–692.
   PubMed Web of Science ®Google Scholar